Urelumab

Urelumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetCD137
Clinical data
Other namesBMS-663513
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6502H9972N1712O2030S44
Molar mass146015.89 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Urelumab (BMS-663513 or anti-4-1BB antibody) is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer and solid tumors.[1]

Urelumab targets the extracellular domain of CD137.[2] It specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells.[3]

The first phase I trial began in 2006 and final results were published in 2015.[4]

Current clinical trials combine urelumab with chemotherapy (NCT00351325), chemoradiation (NCT00461110), ipilimumab (NCT00803374), rituximab (NCT01775631, NCT02420938), cetuximab (NCT02110082), and elotuzumab (NCT02252263), nivolumab (NCT02253992) for metastatic solid tumors, NSCLC, melanoma, B-cell non-Hodgkin lymphoma, colorectal cancer, and multiple myeloma. A biomarker study using CyTOF is also underway.[2]

References

  1. ↑ "Statement On A Nonproprietary Name Adopted By The USAN Council: Urelumab" (PDF). American Medical Association.
  2. 1 2 Yonezawa A, Dutt S, Chester C, Kim J, Kohrt HE (July 2015). "Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy". Clinical Cancer Research. 21 (14): 3113–20. doi:10.1158/1078-0432.CCR-15-0263. PMC 5422104. PMID 25908780.
  3. ↑ "Urelumab". National Cancer Institute.
  4. ↑ Clinical trial number NCT00309023 for "Study of BMS-663513 in Patients With Advanced Cancer" at ClinicalTrials.gov
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.